BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 8017769)

  • 1. The interaction of glycosaminoglycans with heparin cofactor II.
    Tollefsen DM
    Ann N Y Acad Sci; 1994 Apr; 714():21-31. PubMed ID: 8017769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The interaction of glycosaminoglycans with heparin cofactor II: structure and activity of a high-affinity dermatan sulfate hexasaccharide.
    Tollefsen DM
    Adv Exp Med Biol; 1992; 313():167-76. PubMed ID: 1442260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of heparin- and dermatan sulfate-mediated catalysis of thrombin inactivation by heparin cofactor II.
    Liaw PC; Austin RC; Fredenburgh JC; Stafford AR; Weitz JI
    J Biol Chem; 1999 Sep; 274(39):27597-604. PubMed ID: 10488098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Site-directed mutagenesis of arginine 103 and lysine 185 in the proposed glycosaminoglycan-binding site of heparin cofactor II.
    Blinder MA; Tollefsen DM
    J Biol Chem; 1990 Jan; 265(1):286-91. PubMed ID: 2104620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure of a dermatan sulfate hexasaccharide that binds to heparin cofactor II with high affinity.
    Maimone MM; Tollefsen DM
    J Biol Chem; 1990 Oct; 265(30):18263-71. PubMed ID: 2211700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N-Acetylgalactosamine 4,6-O-sulfate residues mediate binding and activation of heparin cofactor II by porcine mucosal dermatan sulfate.
    Halldórsdóttir AM; Zhang L; Tollefsen DM
    Glycobiology; 2006 Aug; 16(8):693-701. PubMed ID: 16624894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The N-terminal acidic domain of heparin cofactor II mediates the inhibition of alpha-thrombin in the presence of glycosaminoglycans.
    Van Deerlin VM; Tollefsen DM
    J Biol Chem; 1991 Oct; 266(30):20223-31. PubMed ID: 1939083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aspartic acid residues 72 and 75 and tyrosine-sulfate 73 of heparin cofactor II promote intramolecular interactions during glycosaminoglycan binding and thrombin inhibition.
    Mitchell JW; Church FC
    J Biol Chem; 2002 May; 277(22):19823-30. PubMed ID: 11856753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heparin cofactor II is regulated allosterically and not primarily by template effects. Studies with mutant thrombins and glycosaminoglycans.
    Sheehan JP; Tollefsen DM; Sadler JE
    J Biol Chem; 1994 Dec; 269(52):32747-51. PubMed ID: 7806495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The preferred pathway of glycosaminoglycan-accelerated inactivation of thrombin by heparin cofactor II.
    Verhamme IM; Bock PE; Jackson CM
    J Biol Chem; 2004 Mar; 279(11):9785-95. PubMed ID: 14701814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular mapping of the thrombin-heparin cofactor II complex.
    Fortenberry YM; Whinna HC; Gentry HR; Myles T; Leung LL; Church FC
    J Biol Chem; 2004 Oct; 279(41):43237-44. PubMed ID: 15292227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycosaminoglycan-binding properties and kinetic characterization of human heparin cofactor II expressed in Escherichia coli.
    Sarilla S; Habib SY; Tollefsen DM; Friedman DB; Arnett DR; Verhamme IM
    Anal Biochem; 2010 Nov; 406(2):166-75. PubMed ID: 20670608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The complete N-terminal extension of heparin cofactor II is required for maximal effectiveness as a thrombin exosite 1 ligand.
    Boyle AJ; Roddick LA; Bhakta V; Lambourne MD; Junop MS; Liaw PC; Weitz JI; Sheffield WP
    BMC Biochem; 2013 Mar; 14():6. PubMed ID: 23496873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reformable intramolecular cross-linking of the N-terminal domain of heparin cofactor II: effects on enzyme inhibition.
    Brinkmeyer S; Eckert R; Ragg H
    Eur J Biochem; 2004 Nov; 271(21):4275-83. PubMed ID: 15511233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altered dermatan sulfate structure and reduced heparin cofactor II-stimulating activity of biglycan and decorin from human atherosclerotic plaque.
    Shirk RA; Parthasarathy N; San Antonio JD; Church FC; Wagner WD
    J Biol Chem; 2000 Jun; 275(24):18085-92. PubMed ID: 10749870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Arginine 200 of heparin cofactor II promotes intramolecular interactions of the acidic domain. Implication for thrombin inhibition.
    Ciaccia AV; Monroe DM; Church FC
    J Biol Chem; 1997 May; 272(22):14074-9. PubMed ID: 9162031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isolation of frog and chicken cDNAs encoding heparin cofactor II.
    Colwell NS; Tollefsen DM
    Thromb Haemost; 1998 Nov; 80(5):784-90. PubMed ID: 9843172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of thrombin anion-binding exosite-I in the formation of thrombin-serpin complexes.
    Myles T; Church FC; Whinna HC; Monard D; Stone SR
    J Biol Chem; 1998 Nov; 273(47):31203-8. PubMed ID: 9813026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ligand binding to thrombin exosite II induces dissociation of the thrombin-heparin cofactor II(L444R) complex.
    Han JH; Tollefsen DM
    Biochemistry; 1998 Mar; 37(9):3203-9. PubMed ID: 9485475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contribution of basic residues of the A helix of heparin cofactor II to heparin- or dermatan sulfate-mediated thrombin inhibition.
    Hayakawa Y; Hirashima Y; Kurimoto M; Hayashi N; Hamada H; Kuwayama N; Endo S
    FEBS Lett; 2002 Jul; 522(1-3):147-50. PubMed ID: 12095635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.